UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $315.77 Million Stake in IQVIA Holdings Inc. $IQV

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 1,634,264 shares of the medical research company’s stock after acquiring an additional 134,997 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in IQVIA were worth $315,772,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the last quarter. Empowered Funds LLC raised its holdings in IQVIA by 102.1% during the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IQVIA in the second quarter worth about $514,000. First Trust Advisors LP boosted its stake in shares of IQVIA by 14.8% during the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after acquiring an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in shares of IQVIA by 5.4% during the 2nd quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after acquiring an additional 1,155 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Eric Sherbet sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last ninety days. 1.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

IQV has been the topic of a number of recent analyst reports. Royal Bank Of Canada raised their price objective on IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research note on Wednesday, July 29th. Barclays reiterated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. BMO Capital Markets upped their price objective on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Price Performance

NYSE:IQV opened at $261.29 on Tuesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $265.25. The company has a fifty day moving average price of $224.00 and a 200 day moving average price of $190.15. The stock has a market cap of $43.01 billion, a P/E ratio of 32.42, a PEG ratio of 2.24 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same period last year, the business posted $2.81 EPS. The business’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.